News
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
Gilead Sciences (NASDAQ:GILD) has reached a $202M deal with a group of attorneys general in the U.S. to settle allegations ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...
Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...
"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...
(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...
2don MSN
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results